Literature DB >> 11025361

Gastrin-mediated alterations in gastric epithelial apoptosis and proliferation in a mastomys rodent model of gastric neoplasia.

M Kidd1, L H Tang, I M Modlin, T Zhang, K Chin, P R Holt, S F Moss.   

Abstract

BACKGROUND/AIMS: Hypergastrinemia secondary to low acid secretion is associated with gastric carcinoid formation in Mastomys. We investigated the effect of gastrin on oxyntic epithelial apoptosis and proliferation in this model.
METHODS: Hypergastrinemia and mucosal hyperplasia were induced by irreversible H(2) receptor blockade with loxtidine. Gastrin levels were normalised in some animals by 10 days' loxtidine withdrawal. Serum gastrin was determined by radioimmunoassay, proliferative, enterochromaffin-like cells and Bcl-2 protein family expression by immunohistochemistry, and apoptotic cells by terminal deoxyuridine nucleotide nick end labeling (TUNEL).
RESULTS: Proliferating cells were increased 4-fold in loxtidine-treated animals, and returned to normal upon loxtidine withdrawal. Enterochromaffin-like cell number increased 2-fold with loxtidine, and did not decrease after withdrawal. Apoptotic epithelial cells were located at the luminal surface and increased 1.8-fold with loxtidine, returning to control levels upon withdrawal. The ratio of proliferative to apoptotic cells was lower in the control and withdrawn groups than in the loxtidine group (0.26+/-0.05 and 0.26+/-0.08 vs. 0.77+/-0.12). With hypergastrinemia, the expression of Bcl-2 and Bak was increased and Bax decreased in the middle of the gland.
CONCLUSION: Hypergastrinemia is associated with alterations in both proliferation and apoptosis in Mastomys gastric mucosa. This may contribute to the pathogenesis of mucosal hyperplasia in this model. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11025361     DOI: 10.1159/000007806

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  8 in total

1.  A clinical perspective on gastric neuroendocrine neoplasia.

Authors:  Ben Lawrence; Mark Kidd; Bernhard Svejda; Irvin Modlin
Journal:  Curr Gastroenterol Rep       Date:  2011-02

2.  Proton pump inhibitors on pancreatic cancer risk and survival.

Authors:  Malcolm D Kearns; Ben Boursi; Yu-Xiao Yang
Journal:  Cancer Epidemiol       Date:  2017-01-02       Impact factor: 2.984

Review 3.  Proton Pump Inhibitor Use and Risk of Gastric Cancer: Current Evidence from Epidemiological Studies and Critical Appraisal.

Authors:  Tahmina Nasrin Poly; Ming-Chin Lin; Shabbir Syed-Abdul; Chih-Wei Huang; Hsuan-Chia Yang; Yu-Chuan Jack Li
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

Review 4.  Importance of gastrin in the pathogenesis and treatment of gastric tumors.

Authors:  Michael D Burkitt; Andrea Varro; D Mark Pritchard
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

5.  Chronic restraint stress promotes gastric epithelial malignant transformation by activating the Akt/p53 signaling pathway via ADRB2.

Authors:  Chuanju Zong; Maoquan Yang; Xiaojing Guo; Wansheng Ji
Journal:  Oncol Lett       Date:  2022-07-05       Impact factor: 3.111

Review 6.  Gastrin, Cholecystokinin, Signaling, and Biological Activities in Cellular Processes.

Authors:  Qiang Zeng; Lei Ou; Wei Wang; Dong-Yu Guo
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-06       Impact factor: 5.555

7.  Gastrin: From Physiology to Gastrointestinal Malignancies.

Authors:  Suzann Duan; Karen Rico; Juanita L Merchant
Journal:  Function (Oxf)       Date:  2021-11-26

8.  Gastrin increases mcl-1 expression in type I gastric carcinoid tumors and a gastric epithelial cell line that expresses the CCK-2 receptor.

Authors:  D M Pritchard; D Berry; S M C Przemeck; F Campbell; S W Edwards; A Varro
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-08-21       Impact factor: 4.052

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.